196 related articles for article (PubMed ID: 17554189)
1. FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model.
Park HS; Chung JW; Jae HJ; Kim YI; Son KR; Lee MJ; Park JH; Kang WJ; Yoon JH; Chung H; Lee K
Korean J Radiol; 2007; 8(3):216-24. PubMed ID: 17554189
[TBL] [Abstract][Full Text] [Related]
2. Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor.
Liapi E; Geschwind JF; Vali M; Khwaja AA; Prieto-Ventura V; Buijs M; Vossen JA; Ganapathy-Kanniappan S; Wahl RL
J Nucl Med; 2011 Feb; 52(2):225-30. PubMed ID: 21233194
[TBL] [Abstract][Full Text] [Related]
3. The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model.
Jae HJ; Chung JW; Park HS; Lee MJ; Lee KC; Kim HC; Yoon JH; Chung H; Park JH
Korean J Radiol; 2009; 10(6):596-603. PubMed ID: 19885316
[TBL] [Abstract][Full Text] [Related]
4. Hepatic intra-arterial injection of 3-bromopyruvate in rabbit VX2 tumor.
Shin SW; Han H; Choo SW; Yoo BC; Park CK; Do YS; Lee JH; Lee DH; Choi D; Choo IW; Kim SS; Lee JY
Acta Radiol; 2006 Dec; 47(10):1036-41. PubMed ID: 17135005
[TBL] [Abstract][Full Text] [Related]
5. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer.
Vali M; Liapi E; Kowalski J; Hong K; Khwaja A; Torbenson MS; Georgiades C; Geschwind JF
J Vasc Interv Radiol; 2007 Jan; 18(1 Pt 1):95-101. PubMed ID: 17296709
[TBL] [Abstract][Full Text] [Related]
6. Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model.
Song SL; Liu JJ; Huang G; Wang ZH; Song YY; Sun XG; Chen T
J Nucl Med; 2008 Feb; 49(2):303-9. PubMed ID: 18199614
[TBL] [Abstract][Full Text] [Related]
7. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study.
Vali M; Vossen JA; Buijs M; Engles JM; Liapi E; Ventura VP; Khwaja A; Acha-Ngwodo O; Ganapathy-Kanniappan S; Syed L; Wahl RL; Geschwind JF
J Pharmacol Exp Ther; 2008 Oct; 327(1):32-7. PubMed ID: 18591216
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET evaluation of therapeutic effects on VX2 liver tumor.
Oya N; Nagata Y; Tamaki N; Takagi T; Murata R; Magata Y; Abe M; Konishi J
J Nucl Med; 1996 Feb; 37(2):296-302. PubMed ID: 8667065
[TBL] [Abstract][Full Text] [Related]
9. [Effects of intra-arterial infusion of 3-bromopyruvate on metastases and survival benefit of hepatic VX2 tumor in rabbits].
Jiang XY; Zhang XP; Huang JH; Luo RG; Miao BJ; Wang Y
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(39):3139-42. PubMed ID: 24417996
[TBL] [Abstract][Full Text] [Related]
10. Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: In vivo investigation in normal rabbit model.
Chang JM; Chung JW; Jae HJ; Eh H; Son KR; Lee KC; Park JH
Acad Radiol; 2007 Jan; 14(1):85-92. PubMed ID: 17178370
[TBL] [Abstract][Full Text] [Related]
11. Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization.
Vossen JA; Buijs M; Syed L; Kutiyanwala F; Kutiyanwala M; Geschwind JF; Vali M
Clin Exp Metastasis; 2008; 25(7):811-7. PubMed ID: 18649116
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of experimental liver tumors using fluorine-18-2-fluoro-2-deoxy-D-glucose PET.
Oya N; Nagata Y; Ishigaki T; Abe M; Tamaki N; Magata Y; Konishi J
J Nucl Med; 1993 Dec; 34(12):2124-9. PubMed ID: 8254399
[TBL] [Abstract][Full Text] [Related]
13. Correlation between hepatic tumor blood flow and glucose utilization in a rabbit liver tumor model.
Stewart EE; Chen X; Hadway J; Lee TY
Radiology; 2006 Jun; 239(3):740-50. PubMed ID: 16621929
[TBL] [Abstract][Full Text] [Related]
14. FDG-MicroPET and diffusion-weighted MR image evaluation of early changes after radiofrequency ablation in implanted VX2 tumors in rabbits.
Ohira T; Okuma T; Matsuoka T; Wada Y; Nakamura K; Watanabe Y; Inoue Y
Cardiovasc Intervent Radiol; 2009 Jan; 32(1):114-20. PubMed ID: 18696151
[TBL] [Abstract][Full Text] [Related]
15. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
Tatsumi M; Nakamoto Y; Traughber B; Marshall LT; Geschwind JF; Wahl RL
Cancer Res; 2003 Oct; 63(19):6252-7. PubMed ID: 14559811
[TBL] [Abstract][Full Text] [Related]
16. Bioevaluation study of 32P-CP-PLLA particle brachytherapy in a rabbit VX2 lung tumor model.
Xu Yp; Yang M; Pan Dh; Wang Lz; Liu L; Huang P; Shao G
Appl Radiat Isot; 2012 Apr; 70(4):583-8. PubMed ID: 22245365
[TBL] [Abstract][Full Text] [Related]
17. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits.
Okuma T; Matsuoka T; Okamura T; Wada Y; Yamamoto A; Oyama Y; Koyama K; Nakamura K; Watanabe Y; Inoue Y
J Nucl Med; 2006 Aug; 47(8):1351-8. PubMed ID: 16883016
[TBL] [Abstract][Full Text] [Related]
19. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT.
Vogt FM; Antoch G; Veit P; Freudenberg LS; Blechschmid N; Diersch O; Bockisch A; Barkhausen J; Kuehl H
J Nucl Med; 2007 Nov; 48(11):1836-44. PubMed ID: 17942811
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.
Kim W; Yoon JH; Jeong JM; Cheon GJ; Lee TS; Yang JI; Park SC; Lee HS
Mol Cancer Ther; 2007 Sep; 6(9):2554-62. PubMed ID: 17876052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
